8-K: Moleculin Biotech's Annamycin Shows Promise in Overcoming Venetoclax Resistance in AML

Moleculin Biotech announced new findings indicating that Annamycin can overcome resistance to Venetoclax in acute myeloid leukemia (AML), with promising preclinical and clinical data.

Summary

• Moleculin Biotech has released new data supporting the effectiveness of Annamycin in treating acute myeloid leukemia (AML), particularly in cases resistant to Venetoclax.
• Preclinical studies show Annamycin's activity in a Venetoclax-resistant AML model, which has been accepted for online publication at the American Society of Hematology (ASH) Annual Meeting.
• Preliminary clinical results from the MB-106 trial indicate that Annamycin combined with Ara-C (AnnAraC) achieved a 60% complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate in patients who had relapsed or were refractory to Venetoclax.
• This 60% CR/CRi rate is more than four times greater than the 12.5% rate reported in a prior publication for salvage therapy using standard of care in similar patients.
• The MB-106 trial also showed a median overall survival of 11.6 months for subjects receiving AnnAraC as a second-line therapy.
• Moleculin is advancing Annamycin into a Phase 3 pivotal trial (MB-108) called the MIRACLE trial, which is expected to begin patient treatment in the first quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data for Annamycin, showing a significant improvement over existing treatments for relapsed AML. The advancement to a Phase 3 trial and the receipt of Fast Track and Orphan Drug Designations further boost the positive sentiment.

Positives

• Annamycin shows significant activity in overcoming Venetoclax resistance in AML.
• The 60% CR/CRi rate in the MB-106 trial is a substantial improvement over historical rates.
• The median overall survival of 11.6 months in second-line therapy is promising.
• Annamycin has received Fast Track and Orphan Drug Designations, which can expedite the approval process.
• The company is moving forward with a Phase 3 pivotal trial, indicating confidence in the drug's potential.

Risks

• The forward-looking statements are subject to risks and uncertainties, including those detailed in the company's SEC filings.
• The success of the Phase 3 trial is not guaranteed, and the drug may not receive regulatory approval.
• The company's expectations may differ materially from actual results.

Future Outlook

Moleculin is focused on advancing Annamycin through the Phase 3 MIRACLE trial, with the goal of obtaining regulatory approval for the treatment of relapsed or refractory AML. The company expects to disclose unblinded data for the first 45 subjects within the next 12 months.

Management Comments

• Jorge Cortes, MD, noted the high relapse rate and limited treatment options for AML patients after Venetoclax therapy.
• Michael Andreeff, MD, PhD, stated that Annamycin combined with Ara-C could significantly advance the standard of care for high-risk AML patients.
• Walter Klemp, Chairman and CEO of Moleculin, expressed confidence in Annamycin's safety and efficacy and its potential to provide a new treatment option in AML.

Industry Context

The announcement highlights a potential breakthrough in treating AML patients who have developed resistance to Venetoclax, a common first-line therapy. This addresses a significant unmet need in the AML treatment landscape, where relapse rates are high and treatment options are limited. The results position Annamycin as a potential competitor to existing salvage therapies.

Comparison to Industry Standards

• The reported 60% CR/CRi rate for Annamycin plus Ara-C in relapsed or refractory AML patients is significantly higher than the 12.5% rate reported in a prior publication for standard of care salvage therapy.
• This suggests that Annamycin could offer a substantial improvement over existing treatment options for patients who have failed Venetoclax-based regimens.
• The median overall survival of 11.6 months for second-line therapy with AnnAraC is also a positive indicator, as survival rates for relapsed AML are typically poor.

Stakeholder Impact

• Shareholders may view the positive clinical data and advancement to Phase 3 as a positive development.
• Patients with relapsed or refractory AML may have a promising new treatment option.
• Physicians may have a new tool to combat Venetoclax resistance in AML.

Next Steps

• The company will present preclinical data at the ASH Annual Meeting in December 2024.
• The abstract will be published in a supplemental issue of Blood in late November 2024.
• Moleculin will initiate patient treatment in the Phase 3 MIRACLE trial (MB-108) in the first quarter of 2025.
• The company expects to disclose unblinded data for the first 45 subjects within the next 12 months.

Key Dates

Keywords

Annamycin, AML, Venetoclax, Leukemia, Cancer, Oncology, Clinical Trial, MB-106, MB-108, MIRACLE Trial, Orphan Drug Designation, Fast Track Status